Mekinist (trametinib)

P2, N=35, Completed, Melanoma Institute Australia | Active, not recruiting --> Completed

Our work redefines an immune-cell death paradox, revealing how tumors exploit IFN-β to evade therapy. We propose CADS as a translational biomarker for identifying tumors reliant on this pathway and validate a mechanism-based combination therapy that selectively targets dormancy-associated death resistance, offering a promising strategy to improve CRC outcomes.

The patient received various treatment regimens, including toripalimab monotherapy, combination therapy with anlotinib, and combination therapy with temozolomide. Ultimately, surgical resection of the pancreatic and spleen metastases revealed a BRAF V600 mutation, permitting successful transition to targeted therapy with dabrafenib plus trametinib...This case report, along with the subsequent literature review, emphasizes the need for continued treatment and vigilance of molecular monitoring in patients with advanced melanoma, as well as the critical role of multidisciplinary team collaboration in managing complex metastases. Surgical resection and targeted therapy might yield favorable outcomes for select patients with melanoma and pancreatic and splenic metastases.

Functional analysis demonstrated increased sensitivity of AZACL2 cells to the BRAF inhibitor dabrafenib and MEK inhibitors including trametinib, compared with BRAF wild-type cell lines. The mutation spectrum was broadly consistent with previous reports, suggesting a conserved molecular landscape across geographic regions. Collectively, these data identify BRAF and HER2 alterations as clinically relevant candidates for molecular diagnostics and targeted therapy in canine pulmonary adenocarcinoma.

Trametinib monotherapy offers limited CB in patients harboring NRAS-mutant malignancies. Future research should further explore the biological and clinical significance of specific NRAS codon mutations to identify biomarkers and optimize treatment approaches.

Progression-free survival was 12.8 months and overall survival reached 44.4 months. This case underscores the importance of early molecular profiling and supports the integration of targeted therapies into routine clinical practice for tumors with limited effective therapeutic options.

Erythrocytosis represents an underrecognized, early, recurrent, and indolent adverse event of antiangiogenic and targeted therapies, particularly RETi, in advanced thyroid cancer. Its biological mechanisms and optimal management strategies warrant further investigation.

Patients with high RCDI exhibited higher sensitivity to several targeted therapies, including Vorinostat and Trametinib. The RCDI model effectively stratifies HCC patients based on RCD-related molecular features, providing a valuable tool for predicting survival and therapeutic responses. The identification of key genes offers new insights into the molecular mechanisms of HCC and potential therapeutic targets.

BRAFV600E-mutant ATC displays distinct clinical features and improved survival when treated with targeted therapy; ddPCR-based liquid biopsy provides a rapid and sensitive method for BRAFV600E detection and may support timely therapeutic decision-making. Serial LB analysis may contribute to disease monitoring and detection of resistance mechanisms in selected patients.

Using two BRAFV600E mutant melanoma cell lines, Mela14 (treatment-resistant) and Mela16 (treatment-naïve), we investigated whether microtumor arrays could restore cancer stem cell (CSC) characteristics, using ABCB5 and CD271 marker expression, and recapitulate PDTX drug response phenotypes to the BRAF/MEK inhibitor combination dabrafenib/trametinib (DT). These findings suggest that polyacrylamide microtumor arrays can reproduce key features of the in vivo melanoma microenvironment, which may enable rapid, reproducible, and clinically relevant drug sensitivity testing. Therefore, this platform offers potential as a complementary preclinical model for personalized medicine and therapeutic discovery in cancer.

Targeted therapy with trametinib achieved partial radiologic response before further progression. The patient remains clinically stable under ongoing therapy and multidisciplinary care. This case underscores the critical role of molecular diagnostics in risk stratification and treatment selection, particularly in infants with atypically aggressive PLGG.

Although paclitaxel and lenvatinib have been used as drug treatments, combination therapy with dabrafenib and trametinib has recently been reported to be effective. Furthermore, lenvatinib, a molecularly targeted agent, shows limited efficacy against ATC and is associated with frequent adverse events. In contrast, combination therapy with dabrafenib and trametinib is considered an effective therapeutic option for patients with BRAF V600E mutation-positive ATC, when appropriate management and monitoring are implemented.